Analysts’ Updated EPS Estimates for August, 24th (ARGX, BZUN, CORT, DAKT, EVTCY, EWBC, FFG, FOE, FUL, GFSZY)

Analysts’ updated eps estimates for Thursday, August 24th:

argenx SE – American Depositary Shares (NASDAQ:ARGX) had its buy rating reiterated by analysts at Cowen and Company.

Baozun (NASDAQ:BZUN) was downgraded by analysts at Zacks Investment Research from a buy rating to a sell rating. According to Zacks, “Baozun Inc. offers digital and e-commerce service primarily in China. The Company’s services include website design, development and hosting, information technology infrastructure, customer service, warehousing and logistics services as well as digital marketing. Baozun Inc. is based in SHANGHAI, China. “

Corcept Therapeutics (NASDAQ:CORT) was given a $18.00 target price by analysts at Piper Jaffray Companies. The firm currently has a buy rating on the stock.

Daktronics (NASDAQ:DAKT) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $11.00 target price on the stock. According to Zacks, “Daktronics Inc. has strong leadership positions in, and is one of the world’s largest suppliers of, electronic scoreboards, computer-programmable displays, and large screen video displays and control systems. The company excels in the control of large display systems, including those that require integration of multiple complex displays showing real-time information, graphics, animation and video. Daktronics designs, manufactures, markets and services display systems for customers around the world in sport, business and transportation applications. “

Evotec AG (NASDAQ:EVTCY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “

East West Bancorp (NASDAQ:EWBC) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $62.00 price target on the stock. According to Zacks, “East West Bancorp, Inc. is the holding company for East West Bank, East West Capital Trust I, East West Capital Trust II and Risk Services, Inc. “

FBL Financial Group (NYSE:FFG) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $77.00 target price on the stock. According to Zacks, “FBL FINANCIAL GROUP, INC. is a holding company and hrough its subsidiaries underwrites, markets and distributes life insurance, annuities, property-casualty insurance and mutual funds to individuals and small businesses in 15 midwestern and western states. The Company has exclusive marketing arrangements with the state Farm Bureau Federations in its territory and targets sales to approximately 700,000 Farm Bureau member families and other rural, small town andsuburban residents through an exclusive agency force. The Company offers a full range of life insurance products. “

Ferro Corporation (NYSE:FOE) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $22.00 price target on the stock. According to Zacks, “FERRO CORP. is a worldwide producer of specialty materials for industry by organic and inorganic chemistry. It operates in 21 countries worldwide. Ferro produces a variety of specialty coatings, colors, ceramics, plastics, chemicals, and related products and services. Ferro’s most important product is frit produced for use in porcelain enamels and ceramic glazes. Ferro specialty materials require a high degree of technical service on an individual customer basis. “

H. B. Fuller (NYSE:FUL) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “H.B. Fuller Company is a worldwide manufacturer and marketer of adhesives, sealants, coatings, paints and other specialty chemical products. The company’s largest worldwide business category is adhesives, sealants and coatings. These products are sold to customers in a wide range of industries, including packaging, woodworking, automotive, aerospace, graphic arts (books/magazines), appliances, filtration, windows, sporting goods, nonwovens, shoes and ceramic tile. “

G4S (NASDAQ:GFSZY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “G4S Plc operates as an integrated security company specializing in the provision of security products, services and solutions. It offers secure solutions, including risk services and consultancy services; access control, CCTV, intruder alarms, fire detection, video analytics and security, and building systems technology integration; mobile security patrol and response services, and alarm receiving and monitoring facilities; secure facilities services; assisting long term unemployed people into work; and manned security services. The Company also provides care and justice services; prisoner escorting; asylum services; electronic monitoring; and police services. It has operations in North America, Europe, Africa, Middle East, Asia/Pacific and Latin America. G4S Plc is based in United Kingdom. “

Glu Mobile (NASDAQ:GLUU) was given a $4.00 price target by analysts at Roth Capital. The firm currently has a buy rating on the stock.

Hanesbrands (NYSE:HBI) was given a $22.00 price target by analysts at Cowen and Company. The firm currently has a hold rating on the stock.

ImmunoCellular Therapeutics (NASDAQ:IMUC) had its hold rating reiterated by analysts at Maxim Group.

Johnson & Johnson (NYSE:JNJ) was given a $147.00 price target by analysts at Cowen and Company. The firm currently has a buy rating on the stock.

Neurocrine Biosciences (NASDAQ:NBIX) was given a $68.00 price target by analysts at Piper Jaffray Companies. The firm currently has a buy rating on the stock.

Southwestern Energy (NYSE:SWN) was given a $8.00 target price by analysts at Piper Jaffray Companies. The firm currently has a hold rating on the stock.

Zoetis (NYSE:ZTS) was given a $70.00 target price by analysts at Cowen and Company. The firm currently has a buy rating on the stock.